Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 5/20 | 0.43 |
| ▸ | BCR | P11274 | 5/20 | 0.43 |
| ▸ | CSNK2A2 | P19784 | 5/20 | 0.39 |
| ▸ | PIM1 | P11309 | 1/20 | 0.39 |
| ▸ | MAP3K8 | P41279 | 6/20 | 0.36 |
| ▸ | MAPK13 | O15264 | 4/20 | 0.36 |
| ▸ | SRC | P12931 | 4/20 | 0.36 |
| ▸ | MAPK12 | P53778 | 4/20 | 0.36 |
| ▸ | MAP2K1 | Q02750 | 4/20 | 0.36 |
| ▸ | MAPK11 | Q15759 | 4/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.36 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.36 |
| ▸ | PRKCG | P05129 | 1/20 | 0.36 |
| ▸ | PRKCB | P05771 | 1/20 | 0.36 |
| ▸ | PRKCA | P17252 | 1/20 | 0.36 |
| ▸ | PRKCH | P24723 | 1/20 | 0.36 |
| ▸ | PRKCI | P41743 | 1/20 | 0.36 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.36 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.36 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13421562 | 0.89 | ABL1 (0.45) | ABL1BCRCSNK2A2PIM1 | |
| SCHEMBL13644195 | 0.87 | CSNK2A2 (0.42) | ABL1BCRCSNK2A2MAP3K8MAPK13 | |
| SCHEMBL3311521 | 0.81 | CSNK2A2 (0.44) | CSNK2A2 | |
| SCHEMBL3311734 | 0.81 | CSNK2A2 (0.48) | CSNK2A2 | |
| SCHEMBL2356589 | 0.80 | CSNK2A2 (0.41) | ABL1BCRCSNK2A2MAP2K1CHEK1 | |
| SCHEMBL3309645 | 0.78 | CSNK2A2 (0.47) | CSNK2A2 | |
| SCHEMBL3313265 | 0.77 | CSNK2A2 (0.32) | ABL1BCRCSNK2A2CSF1R | |
| SCHEMBL3313759 | 0.77 | TYK2 (0.49) | ABL1BCRCSNK2A2PIM1MAP3K8 | |
| SCHEMBL3312928 | 0.76 | CSNK2A2 (0.49) | CSNK2A2 | |
| SCHEMBL3311584 | 0.75 | CSNK2A2 (0.41) | ABL1BCRCSNK2A2MAP3K8MAPK13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8252795-B2 | Imidazopyridazinecarbonitriles useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-08-28 | — | — | US | claimed |
| US-9371328-B2 | Imidazopyridazinecarbonitriles useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-06-21 | — | — | US | disclosed |
| US-9371328-B2 | Imidazopyridazinecarbonitriles useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-06-21 | — | — | US | disclosed |
| US-9371328-B2 | Imidazopyridazinecarbonitriles useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-06-21 | — | — | US | disclosed |
| US-20140179674-A1 | IMIDAZOPYRIDAZINECARBONITRILES USEFUL AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2014-06-26 | — | — | US | disclosed |
| EP-2350081-B1 | IMIDAZOPYRIDAZINECARBONITRILES USEFUL AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2013-07-03 | — | — | EP | disclosed |
| EP-2350081-B1 | IMIDAZOPYRIDAZINECARBONITRILES USEFUL AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2013-07-03 | — | — | EP | disclosed |
| US-20120283241-A1 | IMIDAZOPYRIDAZINECARBONITRILES USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2012-11-08 | — | — | US | disclosed |
| US-20120283241-A1 | IMIDAZOPYRIDAZINECARBONITRILES USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2012-11-08 | — | — | US | disclosed |
| US-8252795-B2 | Imidazopyridazinecarbonitriles useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-08-28 | — | — | US | disclosed |
| US-8252795-B2 | Imidazopyridazinecarbonitriles useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-08-28 | — | — | US | disclosed |
| US-8252795-B2 | Imidazopyridazinecarbonitriles useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-08-28 | — | — | US | disclosed |
| EP-2350081-A1 | IMIDAZOPYRIDAZINECARBONITRILES USEFUL AS KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2011-08-03 | — | — | EP | disclosed |
| US-20100113458-A1 | IMIDAZOPYRIDAZINECARBONITRILES USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-05-06 | — | — | US | disclosed |
| US-20100113458-A1 | IMIDAZOPYRIDAZINECARBONITRILES USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-05-06 | — | — | US | disclosed |
| US-20100113458-A1 | IMIDAZOPYRIDAZINECARBONITRILES USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-05-06 | — | — | US | disclosed |
| WO-2010042699-A1 | IMIDAZOPYRIDAZINECARBONITRILES USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283241-A1 | IMIDAZOPYRIDAZINECARBONITRILES USEFUL AS KINASE INHIBITORS | MAP3K5, MAP3K15, MAP4K2 | ABL1 13/4885BCR 480/4885CSNK2A2 135/4885 |
| US-20100113458-A1 | IMIDAZOPYRIDAZINECARBONITRILES USEFUL AS KINASE INHIBITORS | MAP3K5, MAP3K15, MAP4K2 | ABL1 13/4885BCR 480/4885CSNK2A2 135/4885 |
| US-20140179674-A1 | IMIDAZOPYRIDAZINECARBONITRILES USEFUL AS KINASE INHIBITORS | MAP3K5, MAP3K15, MAP4K2 | ABL1 13/4885BCR 480/4885CSNK2A2 135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.